Valerie Trubnik, MD
Ophthalmology · Mineola, NYNPI 1265682496
Payments from drug & device makers
Across 448 payments — averaging $320.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$68K
- AbbVie$36K
- Aerie Pharmaceuticals, Inc.$18K
- Glaukos Corporation$10K
- Alcon$8K
- Oyster Point Pharma, Inc.$705
- plus $4K from 24 others
Across 1 payment — averaging $2700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$3K
What the payments were for
- Consulting fees$14,89631%
- Speaking & faculty fees$22,19947%
- Travel & lodging$1,3633%
- Food & beverage$9,22619%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 9 | $67,546 |
| AbbVie(2 entities) | 128 | $35,536 |
| Aerie Pharmaceuticals, Inc. | 31 | $17,739 |
| Glaukos Corporation | 24 | $10,161 |
| Alcon | 45 | $7,759 |
| Oyster Point Pharma, Inc. | 32 | $705 |
| NEW World Medical,inc. | 7 | $634 |
| Sun Pharmaceutical Industries Inc. | 34 | $610 |
| Novartis | 19 | $458 |
| Bausch & Lomb Americas Inc. | 19 | $332 |
| Harrow Eye, LLC | 12 | $287 |
| Thea Pharma Inc. | 12 | $249 |
| Mallinckrodt Hospital Products Inc. | 9 | $236 |
| Amgen(2 entities) | 12 | $232 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $229 |
| Sight Sciences, Inc. | 9 | $214 |
| Tarsus Pharmaceuticals, Inc. | 7 | $156 |
| Kala Pharmaceuticals, Inc. | 6 | $126 |
| Ocular Therapeutix, Inc. | 4 | $66 |
| Dompe US, Inc. | 2 | $61 |
| Rxsight Inc | 2 | $56 |
| Biotissue Holdings Inc. | 2 | $51 |
| Rayner Intraocular Lenses Limited | 2 | $48 |
| Genentech USA, Inc. | 2 | $47 |
| Carl Zeiss Meditec Cataract Technology Inc. | 2 | $30 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $22 |
| Beaver-visitec International, Inc. | 1 | $21 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$29,689
- Rhopressa$24,016
- Travoprost Intraocular Implant - iDose$6,272
- Hydrus Microstent$1,950
- Voyager DSLT$1,950
- iDose TR$1,100
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$1,100
- iDose$825
- Kahook Dual Blade$389
- Streamline Surgical System$389
- Ahmed Glaucoma Valve$389
- iDoseTR$291
- iStent Infinite$181
How this compares
$143,680 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 231 | $269,196 |
| LumiganBimatoprost | 184 | $103,730 |
| XiidraLifitegrast | 61 | $79,556 |
| MieboPerfluorohexyloctane/Pf | 81 | $76,638 |
| RhopressaNetarsudil Mesylate | 100 | $66,128 |
| RocklatanNetarsudil Mesylat/Latanoprost | 104 | $64,825 |
| Cyclosporine | 99 | $45,369 |
| CombiganBrimonidine Tartrate/Timolol | 122 | $43,747 |
| VyzultaLatanoprostene Bunod | 49 | $33,476 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 124 | $30,927 |
| Alphagan PBrimonidine Tartrate | 58 | $24,234 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 179 | $23,967 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 111 | $19,185 |
| ProlensaBromfenac Sodium | 50 | $17,215 |
| Timolol MaleateTimolol Maleate/Pf | 39 | $17,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P, Restasis Multidose | $35,536 | $454,493611 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $332 | $189,671191 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $17,739 | $130,952204 claims |
| AlconSimbrinza, Azopt | $7,759 | $38,664139 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Loteprednol Etabonate | $229 | $32,745132 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $705 | $16,10416 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $610 | $11,92017 claims |
| NovartisTravatan Z | $458 | $9,77913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Mineola
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.